Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

9-15-2022

Ehrlich tumor induces TRPV1-dependent evoked and non-evoked
pain-like behavior in mice
Mariana M Bertozzi
Londrina State University

Telma Saraiva-Santos
Londrina State University

Tiago H Zaninelli
Londrina State University

Felipe A Pinho-Ribeiro
Washington University School of Medicine in St. Louis

Victor Fattori
Londrina State University

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Bertozzi, Mariana M; Saraiva-Santos, Telma; Zaninelli, Tiago H; Pinho-Ribeiro, Felipe A; Fattori, Victor;
Staurengo-Ferrari, Larissa; Ferraz, Camila R; Domiciano, Talita P; Calixto-Campos, Cassia; Borghi, Sergio
M; Zarpelon, Ana C; Cunha, Thiago M; Casagrande, Rubia; and Verri, Waldiceu A, "Ehrlich tumor induces
TRPV1-dependent evoked and non-evoked pain-like behavior in mice." Brain Sciences. 12, 9. 1247 (2022).
https://digitalcommons.wustl.edu/oa_4/550

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors
Mariana M Bertozzi, Telma Saraiva-Santos, Tiago H Zaninelli, Felipe A Pinho-Ribeiro, Victor Fattori, Larissa
Staurengo-Ferrari, Camila R Ferraz, Talita P Domiciano, Cassia Calixto-Campos, Sergio M Borghi, Ana C
Zarpelon, Thiago M Cunha, Rubia Casagrande, and Waldiceu A Verri

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/oa_4/550

brain
sciences
Communication

Ehrlich Tumor Induces TRPV1-Dependent Evoked and
Non-Evoked Pain-like Behavior in Mice
Mariana M. Bertozzi 1 , Telma Saraiva-Santos 1 , Tiago H. Zaninelli 1 , Felipe A. Pinho-Ribeiro 1,2 , Victor Fattori 1 ,
Larissa Staurengo-Ferrari 1 , Camila R. Ferraz 1 , Talita P. Domiciano 1 , Cassia Calixto-Campos 1 ,
Sergio M. Borghi 1,3 , Ana C. Zarpelon 1 , Thiago M. Cunha 4 , Rubia Casagrande 5 and Waldiceu A. Verri 1, *,†
1

2

3
4

5

*
†

Citation: Bertozzi, M.M.;
Saraiva-Santos, T.; Zaninelli, T.H.;
Pinho-Ribeiro, F.A.; Fattori, V.;
Staurengo-Ferrari, L.; Ferraz, C.R.;
Domiciano, T.P.; Calixto-Campos, C.;
Borghi, S.M.; et al. Ehrlich Tumor
Induces TRPV1-Dependent Evoked
and Non-Evoked Pain-like Behavior
in Mice. Brain Sci. 2022, 12, 1247.
https://doi.org/10.3390/
brainsci12091247
Academic Editors: Enrique Velasco,
Karel Talavera and Víctor
M. Meseguer
Received: 20 August 2022
Accepted: 11 September 2022
Published: 15 September 2022
Publisher’s Note: MDPI stays neutral

Laboratory of Pain, Inflammation, Neuropathy, and Cancer, Department of Pathology, Center of Biological
Sciences, Londrina State University, Londrina 86057-970, PR, Brazil
Division of Dermatology, Department of Medicine, Washington University School of Medicine,
St. Louis, MO 63110, USA
Center for Research in Health Sciences, University of Northern Londrina, Londrina 86041-120, PR, Brazil
Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes,
Ribeirão Preto 14049-900, SP, Brazil
Department of Pharmaceutical Sciences, Center of Health Science, Londrina State University,
Londrina 86038-440, PR, Brazil
Correspondence: waverri@uel.br or waldiceujr@yahoo.com.br; Tel.: +55-43-3371-4979; Fax: +55-43-3371-4387
Current address: Departamento de Ciências Patológicas, Universidade Estadual de Londrina, Rodovia Celso
Garcia Cid Km480 PR445, P.O. Box 10.011, Londrina 86057-970, PR, Brazil.

Abstract: We standardized a model by injecting Ehrlich tumor cells into the paw to evaluate cancer pain mechanisms and pharmacological treatments. Opioid treatment, but not cyclooxygenase
inhibitor or tricyclic antidepressant treatments reduces Ehrlich tumor pain. To best use this model
for drug screening it is essential to understand its pathophysiological mechanisms. Herein, we
investigated the contribution of the transient receptor potential cation channel subfamily V member
1 (TRPV1) in the Ehrlich tumor-induced pain model. Dorsal root ganglia (DRG) neurons from the
Ehrlich tumor mice presented higher activity (calcium levels using fluo-4 fluorescent probe) and an
increased response to capsaicin (TRPV1 agonist) than the saline-injected animals (p < 0.05). We also
observed diminished mechanical (electronic von Frey) and thermal (hot plate) hyperalgesia, paw
flinching, and normalization of weight distribution imbalance in TRPV1 deficient mice (p < 0.05).
On the other hand, TRPV1 deficiency did not alter paw volume or weight, indicating no significant
alteration in tumor growth. Intrathecal injection of AMG9810 (TRPV1 antagonist) reduced ongoing
Ehrlich tumor-triggered mechanical and thermal hyperalgesia (p < 0.05). Therefore, the contribution
of TRPV1 to Ehrlich tumor pain behavior was revealed by genetic and pharmacological approaches,
thus, supporting the use of this model to investigate TRPV1-targeting therapies for the treatment of
cancer pain.
Keywords: AMG9810; calcium imaging; cancer pain; dorsal root ganglia; Ehrlich tumor; mechanical
hyperalgesia; nociception; pain; thermal hyperalgesia; TRPV1
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In 1905, Paul Ehrlich described a mammary adenocarcinoma that was found to develop spontaneously in mice [1]. Ehrlich tumor cells are maintained by intraperitoneal
(i.p.) passages in an ascitic form, which is used for pharmacological screening and pathophysiological investigation [2,3]. The Ehrlich tumor cells can also develop as a solid tumor
when injected subcutaneously [4]. We developed an Ehrlich tumor pain model by injecting these cells subcutaneously into the plantar side of the hind paw of mice [5]. In this
model, we observed that Ehrlich tumor cells induce pain-like behavior that was amenable
to treatment with the opioid morphine. On the other hand, the cyclooxygenase inhibitor
indomethacin and the tricyclic antidepressant amitriptyline were ineffective in altering
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pain-like behavior [5]. Breast cancer patients report pain in other phases in addition to the
metastasis phase. In fact, 1/3 of those patients report spontaneous pain in the lump and
when pressure is applied during examination [6]. Preoperative breast pain correlates with
phantom breast pain syndrome, and adequate analgesia before mastectomy can diminish
phantom breast pain syndrome [7]. Our interpretation is that the model developed by our
group resembles preoperative breast cancer pain in the lump and could be useful to screen
and understand the pathophysiological mechanisms of such conditions, which ultimately
can lead to novel treatments [5].
Transient receptor potential cation channel subfamily V member 1 (TRPV1) is important in pain processing. Indeed, most nociceptive C fibers express TRPV1 and serve
to sense peripheral alterations and transmit these nociceptive inputs to the spinal cord.
TRPV1 senses many types of alterations: for instance, TRPV1 senses noxious heat (>42 ◦ C),
extreme acidic or basic pH, lipids such as lysophosphatidic acid, chemicals with pungent
characteristics (e.g., chili pepper compound capsaicin), and toxins (e.g., vanillotoxins) [8,9].
Supporting the significance of TRPV1 in cancer pain, targeting TRPV1 with genetic and
pharmacological approaches reduces pain in bone cancer [10,11], squamous cell carcinoma [12], and pancreatic cancer [13]. Although each cancer type has its own peculiarities,
identifying drug-targetable pathophysiological mechanisms is essential to developing novel
analgesic therapies. Therefore, in this study, we evaluated the contribution of TRPV1 to
Ehrlich tumor pain.
2. Material and Methods
2.1. Animals
Male C57BL/6 and TRPV1 deficient (TRPV1-/- , C57BL/6 background) mice for this
study were from Londrina State University (Paraná, Brazil) and Ribeirão Preto Medical School, University of Sao Paulo (São Paulo, Brazil), respectively. All mice weighed
22 ± 1 g, 8–9 weeks-old, and were housed in standard clear plastic cages, with a standard
light/dark cycle of 12:12 h, and had food and water ad libitum. The temperature was
maintained at 21 ± 1 ◦ C and behavioral experiments occurred in the light cycle between
9 a.m. and 5 p.m. To achieve equal sample size at all time points, mice were separated by
block randomization. The ARRIVE 2.0 (Lilley et al., 2020) and International Association for
Study of Pain (IASP) guidelines were followed and the study was designed to minimize the
number of animals and their suffering as much as possible. Prior approval by the Londrina
State University Ethics Committee on Animal Research and Welfare was obtained (process
number 14543.2013.03). Inhalation of isoflurane (5% oxygen using a precision vaporizer)
was applied to euthanize animals, and then decapitation was performed as a confirmatory
method. This study used a total of 144 C57BL/6 mice and 20 TRPV1-/- C57BL/6 mice.
2.2. Experimental Procedures
Ehrlich cells (1 × 106 ) were suspended in sterile saline (25 µL) and administrated by
subcutaneous plantar injection (intraplantar [i.pl.]). On the 12th day, mice were euthanized
with isoflurane 5%, and the DRG from L4-L6 were collected, processed to isolate neurons,
and cultured overnight. Fluo-4-AM probe loading into DRG neurons allowed detecting by
fluorescence the kinetics of intracellular calcium as a surrogate measure of neuronal activity.
Basal levels of calcium and upon capsaicin stimulation were quantitated by calcium imaging
using a confocal microscope. In another set of experiments, TRPV1-/- and C57BL/6 mice
received an i.pl. injection of Ehrlich tumor cells. Mechanical hyperalgesia (electronic
aesthesiometer, an apparatus similar to von Frey filaments, but in an electronic version),
thermal hyperalgesia (hot plate apparatus), paw thickness (caliper), and the distribution
of weight between the hind paws (static weight bearing apparatus) were determined at
the basal time point and every two days until the 12th day. After these measurements
were taken, the animals were euthanized, and the paws were collected and weighed. To
investigate the effects of TRPV1 pharmacological inhibition, Ehrlich tumor cells (i.pl.) were
administered to C57BL/6 mice and mechanical and thermal hyperalgesia were assessed
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at baseline (before injection) and on the 8th day post Ehrlich tumor injection. On the 8th
day post Ehrlich tumor administration, mice were treated with AMG9810 (intrathecally,
100 nmols) or vehicle (2% DMSO in saline), and mechanical and thermal hyperalgesia were
evaluated at the indicated time points. The experimental conditions, measurement time
points, Ehrlich tumor cell load, and AMG9810 dose of treatment were determined in prior
studies [5,14,15].
2.3. Calcium Imaging
We followed a prior description of calcium imaging in DRG neurons [15]. On the
12th day after stimulus, C57BL/6 Ehrlich- or saline-stimulated DRG neurons were dissected
into Neurobasal-A medium (Life Technologies, Thermo Fisher Scientific, Waltham, MA,
USA) following a dissociation step using enzymes (collagenase A [1 mg/mL]/dispase II
[2.4 U/mL] RocheApplied Sciences, Indianapolis, IN, USA) diluted in HEPES-buffered
saline medium (MilliporeSigma, Burlington, MA, USA) and incubated at 37 ◦ C for 15 min.
Following the dissociation step the cells were centrifuged for 5 min at 300× g. The cells
were then resuspended in 800 µL of DMEM supplemented with 10% FBS and DNase I.
Glass Pasteur pipettes of progressively decreasing sizes were sequentially used to dissociate DRG neurons. This step was followed by centrifugation of 30 min at 1200 rpm,
applying a 15% BSA gradient. The resulting pellet consisted of DRG neurons, which were
resuspended, counted and plated in Neurobasal-A medium containing nerve growth factor
(NGF, 50 ng/mL, Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA). We
used a total of 5000 DRG neurons per dish, which were plated overnight on culture dishes
with a laminin coating. On the following day, DRG cells were loaded with 1.2 µM of
Fluo-4AM in Neurobasal-A medium and incubated at 37 ◦ C for 30 min. Neurons were
washed with Hanks’ Balanced Salt Solution three times (HBSS calcium, magnesium, no
phenol red, GIBCO, #14025092, Waltham, MA, USA). Fluorescence imaging was carried out
with a TCS SP8 Confocal Microscope (Leica Microsystems, Mannheim, Germany). To assess
TRPV1 activation, DRG plates were recorded for a total time of 7 min, which was divided
into: baseline values/initial reading (2 min), TRPV1 stimulation with its agonist capsaicin
(100 nM in HBSS, MilliporeSigma, Burlington, MA, USA) for up to 4 min, and then KCl
solution (final concentration was 40 mM) for the remainder of the recording time. The TCS
SP8 confocal microscope used the LAS X Software (Leica Microsystems, Mannheim, Germany) [16–20], which was applied to analyze the mean fluorescence intensity representing
calcium influx.
2.4. Mechanical Hyperalgesia
The von Frey’s filaments evolved into an electronic apparatus that can be used with
interchangeable probes while maintaining a fixed probe and area of contact during a set
of experiments. This testing is described to measure mechanical hyperalgesia when there
is a basal response and alteration following stimulation and treatments [14]. Similarly to
other behavioral testing, animals must be placed in a quiet room and gently placed in cages
(12 × 10 × 17 cm) that allow access to the paws from below through wire grid floors. At least
45 min of habituation to the testing room must be carried out on the day of the experiment;
however, prior sessions of habituation lasting 60 min were also conducted on the four
consecutive days leading up to the experiment. Following habituation on the day of the
experiment, the handheld force transducer (electronic aesthesiometer, Insight instruments,
Ribeirao Preto, SP, Brazil) [14] was used to apply a perpendicular stimulation on the hind
paw. A 0.5 mm2 polypropylene tip was placed in the handheld force transducer to allow the
stimulation of a constant area. The endpoint was characterized by the removal and flinching
of both hind paws. The apparatus records the measured value automatically. Measurements
were performed in basal conditions as well as after stimulation and treatment. The mean
mechanical withdrawal threshold of three values (in grams) is shown in figures for each
time point during the 12 days. An ongoing TRPV1-blocking evaluation was performed
for the pharmacological treatment; the mechanical threshold was determined before, 1 h,
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3 h, 5 h, and 7 h after intrathecal treatment with AMG8910 (100 nmols, 10 µL, Cayman
Chemical, Ann Arbor, MI, USA) [21]. The investigators were blinded to the treatment.
2.5. Thermal Hyperalgesia
A hot plate apparatus was set at 52 ± 1 ◦ C to assess heat thermal hyperalgesia [22].
The experimenter was trained to identify hind paw removal from the plate and immediate
flinching or licking behaviors, which were considered the characteristic endpoint. The
response latency was recorded before Ehrlich tumor cells injection (i.pl.) and every two days
up to the 12th day. Heat thermal hyperalgesia was also determined on the 8th day, before,
1 h, 3 h, 5 h, and 7 h after intrathecal treatment with AMG8910 (100 nmols, 10 µL) [21].
Considering tissue damage can occur depending on the time of exposure, we used a cut-off
of 20 s [22]. The investigators were blinded to the treatment.
2.6. Tumor Growth: Paw Thickness and Paw Weight
Paw thickness was determined using an analog caliper thickness gauge (Mitutoyo
7301 A, Mitutoyo Corporation, Kanagawa, Japan) [19,20] before and after Ehrlich tumor
cells injection at the indicated time points (every two days). Paw thickness/tumor growth
was quantitated in mm [23]. At the end of the 12 days, the weight of the contra and
ipsilateral paws were compared, and the delta paw weight was evaluated as a measure of
tumor growth. Paw weight was presented as ∆ipsi-contra lateral grams (g) [24].
2.7. Static Weight Bearing (SWB)
Disability in weight distribution in the mice’s paws was evaluated before and after
induction of cancer-related pain for 12 days. This analysis was made using an apparatus
(Model BIO-SWB-TOUCH-M, Bioseb, France) [25,26] specifically developed to assess SWB.
Similarly to the other tests, the mice were handled gently in a quiet temperature-controlled
room and underwent four days of habituation. The apparatus consists of an acrylic chamber
with two pressure plates in which the hind paws are placed. Mice were placed into an
acrylic chamber allowing the mice to adjust their spontaneous positioning. The apparatus
quantitates the weight value distributed to each sensor [27]. We used the mean of three
measurements at 0 (baseline value) and after Ehrlich Tumor Cells injection (1 × 106 cells,
25 µL in sterile saline, i.pl.) to calculate the Right/Left paw ratio. Measurements were
performed every two days after induction and until day 12. The investigators were blinded
to the groups.
2.8. Statistical Analysis
Results are presented as the mean ± SEM for parametric data and median + range
for non-parametric data. To this end, we used Shapiro–Wilk normality test and BrownForsythe homogeneity test. In in vitro experiments, a n of 2 plates of DRG neuron cultures
were used in each group per experiment, and each plate was a pool of DRGs of 10 animals.
These in vitro experiments were performed twice and the results are shown as the mean of
each experiment, thus each dot is the mean of a separate in vitro experiment. For in vivo
experiments, a n of 10 mice was used in each group for the effect of TRPV1 deficiency,
and a n of 8 mice was used in each group for the experiments with AMG9810 intrathecal
treatment. Data were analyzed using the software GraphPad Prism version 9.2 (La Jolla,
CA, USA). Data from experiments of multiple time points and containing at least three
groups for comparison (mechanical, thermal hyperalgesia, paw thickness, paw weight, and
static weight bearing) were analyzed using Kruskal–Wallis followed by Dunn post-test
or two-way repeated measure analysis of variance (ANOVA) followed by Tukey’s post
hoc, depending on whether results were non-parametric or parametric, respectively. For
parametric data from experiments with a single time point, one-way ANOVA, followed
by Tukey’s post hoc, was used. Statistical differences were considered significant when
p < 0.05.

Brain Sci. 2022, 12, 1247

and static weight bearing) were analyzed using Kruskal–Wallis followed by Dunn posttest or two-way repeated measure analysis of variance (ANOVA) followed by Tukey’s
post hoc, depending on whether results were non-parametric or parametric, respectively.
For parametric data from experiments with a single time point, one-way ANOVA,
followed by Tukey’s post hoc, was used. Statistical differences were considered significant
5 of 12
when p < 0.05.
3. Results
3. Results
3.1. Ehrlich Tumor Cells Induce DRG Neuronal Activation and Enhance Capsaicin Response
3.1. Ehrlich Tumor Cells Induce DRG Neuronal Activation and Enhance Capsaicin Response
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activation of DRG neurons. Peak pain is achieved on the 8th day post-tumor injection and
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calcium imaging as a surrogate for neuronal activation. Plantar Ehrlich tumor cells
imaging as a surrogate for neuronal activation. Plantar Ehrlich tumor cells increased
increased the basal levels of intracellular calcium and the capsaicin-triggered influx
the basal levels of intracellular calcium and the capsaicin-triggered influx (Figure 1A,B).
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DRG neurons of mice bearing plantar Ehrlich tumor cells presented a higher percentage
higher percentage of activated neurons at baseline conditions with augmented capsaicin
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(D) Tracers of mean fluorescence intensity of calcium influx of the baseline (0-s mark) and following
capsaicin stimulation (120 s mark, TRPV1 agonist). The black line refers to the Saline-stimulated
DRGs, and the red line refers to the Ehrlich tumor cells-stimulated DRGs. (E) Quantification of
mean fluorescence intensity of calcium influx of baseline (0-s mark) and following the stimulus with
capsaicin (120-s mark). n = 2 DRG culture plates per group per experiment. Each plate is a neuronal
culture pooled from 10 mice. Two independent experiments were performed, and plotted data are the
mean of both experiments. Results are expressed as median + range. (* p < 0.05 vs. saline). Statistical
information can be found at Table S1.
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zero. Behavior measures were performed after injecting the stimuli to set up the baseline. After
the induction of the model, the behavior parameters were performed every two days up to the
12th day. (B,C) Mechanical and thermal hyperalgesia were evaluated using an electronic version of
von Frey filaments and hot plate apparatus, respectively. (D) Paw thickness was evaluated using
analog calipers, expressing the results in mm. In addition, the ipsilateral and contralateral paws
were weighed, and the delta in paw weight was evaluated as a measure of tumor growth (E). The
depletion of TRPV1 in mice did not alter the pattern of tumor growth. Results are presented as the
mean ± SEM of mechanical threshold in grams (electronic von Frey) or heat thermal threshold latency
in seconds (hot plate). n = 10 mice per group (* p < 0.05 vs. saline group; # p < 0.05 vs. Ehrlich tumor
cells group. (E) Results are expressed as median + range of paw weight ratio. n = 10 mice per group
(* p < 0.05 vs. saline group). (F) SWB was used as a non-reflexive method of pain measurement. The
heat map shows Right/Left rear paw ratio of each mouse. Results are presented as the weight ratio
of Right/Left rear paw. n = 10 mice per group (* p < 0.05 vs. saline group; # p < 0.05 vs. Ehrlich tumor
cells group). Statistical information can be found at Table S2.
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6 cells, 25 µL paw). Furthermore, on the 8th day, when peak pain-like behavior was
tumor
cellscells
(106(10
cells,
25 µL paw). Furthermore, on the 8th day, when peak pain-like behavior was achieved,
AMG9810 (100 nM, 10 µL intrathecal, competitive antagonist of TRPV1) was administered, and
animals were evaluated 1 h, 3 h, 5 h, and 7 h after intrathecal treatment. (B) Ehrlich tumors triggered
ongoing mechanical hyperalgesia and (C) thermal hyperalgesia and were reduced by treatment
with AMG9810 compared to the vehicle (2% dimethyl sulfoxide in saline)-treated group. Results are
presented as the mean ± SEM of mechanical threshold in grams (von Frey) or heat thermal threshold
latency in seconds (hot plate). n = 8 mice per group (* p < 0.05 vs. saline group; # p < 0.05 vs. Ehrlich
tumor cells group. Statistical information can be found at Table S3.

4. Discussion
The present work shows that Ehrlich tumor cells can induce the activation of DRG neurons and enhance neuronal activation upon capsaicin stimulation. Corroborating these data,
interfering with TRPV1 using genetic and pharmacological approaches reduced Ehrlich
tumor-triggered pain-like behavior without affecting tumor growth. To our knowledge, this
is the first study demonstrating TRPV1 contribution to Ehrlich tumor-induced pathology.
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TRPV1 expression characterizes non-myelinated peptidergic neurons called C-fibers,
which mainly function as nociceptors, although some of the C-fibers also contribute to
pruritus [28–31]. These polymodal nociceptors are involved in a great variety of painful
conditions ranging from inflammatory pain to neuropathic pain, complex regional pain
syndrome type 1, and cancer pain [32,33]. For instance, in inflammatory pain, in addition to neurotransmission of nociceptive inputs, TRPV1+ neurons, through the release
of neuropeptides, participate in generating neurogenic inflammation and communicate
with immune cells, regulating their recruitment and function such as phagocytosis [18].
Thus, TRPV1+ neurons have a role in immune regulation during disease. Similarly, cancer
pain also involves the interaction of cancer cells, immune cells, and neurons [34]. In a
model of melanoma, conditional knockdown or ablation of nociceptive neurons led to
enhanced tumor progression [35,36]. These data support that nociceptive neurons may
have an endogenous protective role against cancer progression. However, TRPV1 deficiency did not alter paw thickness and paw weight. Although these are relatively gross
measurements, any significant effect on tumor progression can be detected using such
parameters [24,37,38]. Thus, it is likely that TRPV1+ neurons are not major players in
shaping Ehrlich tumor growth.
This lack of contribution of TRPV1+ neurons to neuro-immune-cancer interactions
supports the rationale that as TRPV1 deficiency reduces pain-like behavior, the major
function of this TRP channel in the Ehrlich tumor model is neuronal activation and neurotransmission of nociceptive inputs. Evidence supports that tumor cells cause an acidic
environment and TRPV1 senses the enhancement of protons in tissues, leading to neuronal
activation and pain [39–41]. Ehrlich tumor cells also trigger the production of hyperalgesic
cytokines [38] that sensitize nociceptor neurons through the increase in activity and expression of ion channels [33,42,43]. Therefore, the present results are consistent with the idea
that Ehrlich tumor progression would enhance pain-like behavior over time, and TRPV1
inhibition would reduce pain without a significant role in tumor progression.
We used two approaches to target TRPV1. The TRPV1 deficiency was used to verify its
contribution over time and offers the complete deletion in the host. The pharmacological
inhibition using AMG9810 was used to verify whether TRPV1 inhibition would have an
effect against ongoing pain, and to confirm whether the effect of TRPV1 deficiency is
related to the targeted deletion or a mistargeted adaptation. Furthermore, with AMG9810,
we could use the intrathecal treatment to isolate its effect in two anatomic regions, the
DRG neurons and spinal cord, instead of a complete animal deletion considering evidence
supporting peripheral immune cells such as macrophages also express TRPV1 [44–46].
These approaches indicate that in Ehrlich tumors, TRPV1 contributes to pain without
affecting tumor progression; thus, therapies targeting TRPV1 could be useful. There are
other options for interfering with TRPV1 activity. For instance, evidence supports that
phosphorylation by PKC (protein kinase C) of the TRPV1 S801 contributes to ligandinduced activation of this channel but not to heat activation, as observed by knock-in
alanine in TRPV1 S801 [47].
TRPV1 is straightforwardly related to thermal hyperalgesia and overt pain-like behavior such as paw flinching, which is a result of the activation of such channels [48–51].
However, inhibiting TRPV1 also results in reduced mechanical hyperalgesia [52–55]. This
outcome might be related to the release of neuropeptides by TRPV1 neurons, which can
activate immune cells such as macrophages [56]. In turn, macrophages would produce
mediators that sensitize nociceptor neurons involved in other pain modalities such as the
mechano-sensation, as is the case of a non-peptidergic neuronal population characterized
by the binding of isolectin B4 and expression of the Mrg family of G-protein-coupled
receptors subfamily D [28,57]. However, as discussed above, a possible neuro-immune
interaction was insufficient to alter Ehrlich tumor progression in the context of TRPV1
deficiency.
Our study aimed at investigating the contribution of the primary afferent nociceptive
neurons expressing TRPV1 in the nociceptive behaviors triggered upon Ehrlich tumor
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administration in mice. We considered that the primary afferent neurons are in contact with
the tumor cells and make this communication between the peripheral tissues and the spinal
cord, making them an important group of cells. However, it is important to mention other
possibilities for future studies. As far as we know, there is no study investigating central
sensitization in the Ehrlich tumor model or whether TRPV1+ primary afferent neurons or
afferent terminals of TRPV1+ neurons in the spinal cord contribute to central sensitization
in this model. For instance, in the spinal cord dorsal horn, TRPV1+ glutamatergic neurons
functionally contribute to excitatory neurotransmission [58]. Spinal NMDA (N-methyl-Daspartate) is important in cancer pain. Disrupting the neuronal transport of NR2B (NMDA
receptor containing a 2B subunit) in the spinal cord reduces the bone pain caused by
injecting fibrosarcoma NCTC 2472 cells into the femur [59]. Evidence also supports that
glutamatergic signaling via NR2B activates neuronal PKCγ (protein kinase C gamma) as a
mechanism to induce central sensitization in cancer bone pain [60]. Thus, it is also possible
that spinal TRPV1+ neuronal afferent terminals contribute to central sensitization in Ehrlich
tumor pain via glutamate, although this hypothesis remains to be investigated.
5. Conclusions
In conclusion, we demonstrate that TRPV1 is involved in Ehrlich tumor pain-like
behavior without interference in tumor progression. This mechanism was unknown for
this model, thus, further validating Ehrlich tumor as a pre-clinical in vivo model for
investigating disease mechanisms and drug development in cancer.
Supplementary Materials: The following supporting information can be downloaded at: https://
www.mdpi.com/article/10.3390/brainsci12091247/s1, Table S1: Statistical information from results
shown in Figure 1; Table S2: Statistical information from results shown in Figure 2; Table S3: Statistical
information from results shown in Figure 3.
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